Latest & greatest articles for chronic kidney disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for chronic kidney disease

1. Commentary on NICE guideline (NG136) ‘Hypertension in adults: diagnosis and management’ including proposals for blood pressure management in patients with chronic kidney disease

/80 mmHg is likely to be beneficial in the majority of individuals with CKD and treating to this target should be considered in all patients. Commentary on NICE guideline (NG136) ‘Hypertension in adults: diagnosis and management’ 2021 11 Renal Association proposal – blood pressure target for individuals with Chronic Kidney Disease 5.1 We propose aiming for a blood pressure target of <130/80 mmHg for patients with chronic kidney disease to improve cardiovascular outcomes if, following a shared (...) Commentary on NICE guideline (NG136) ‘Hypertension in adults: diagnosis and management’ including proposals for blood pressure management in patients with chronic kidney disease Commentary on NICE guideline (NG136) ‘Hypertension in adults: diagnosis and management’ including proposals for blood pressure management in patients with chronic kidney disease Authors: Dr Richard Fish University Hospitals of North Midlands NHS Trust Dr Nihil Chitalia Dartford and Gravesham NHS Trust Dr Timothy Doulton

2021 Renal Association

2. Effect of CPAP Therapy on Kidney Function in Patients With Chronic Kidney Disease: A Pilot Randomized Controlled Trial

Effect of CPAP Therapy on Kidney Function in Patients With Chronic Kidney Disease: A Pilot Randomized Controlled Trial Effect of CPAP Therapy on Kidney Function in Patients With Chronic Kidney Disease: A Pilot Randomized Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 Information Show account info Close (...) RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Chest Actions . 2020 Dec 13;S0012-3692(20)35354-X. doi: 10.1016/j.chest.2020.11.052. Online ahead of print. Effect of CPAP Therapy on Kidney Function in Patients With Chronic Kidney Disease: A Pilot Randomized Controlled Trial , , , , , , Affiliations Expand Affiliations 1 Sleep Centre, Foothills Medical Centre, University of Calgary, Calgary, AB, Canada; Libin Cardiovascular Institute

2021 EvidenceUpdates

3. Exercise and Lifestyle in Chronic Kidney Disease

such as elevations in blood pressure. Improving physical activity levels in line with current recommendations leads to reduced risk of the development of diabetes, stroke and some cancers (e.g. colon and breast cancer). 2 With the benefits in the general population clear, research has focussed on understanding whether similar benefits are noted in those with non-dialysis Chronic Kidney Disease (CKD). CKD is a long-term condition with a significant proportion of those affected never reaching end-stage renal (...) training: a substudy of Renal Exercise (RENEXC)—a randomized controlled trial. Nephrol Dial Transplant. 2019;1–9. 29. Castaneda C, Gordon PL, Parker RC, Uhlin KL, Roubenoff R, Levey AS. Resistance Training to Reduce the Malnutrition-Inflammation Complex Syndrome of Chronic Kidney Disease. Am J Kidney Dis. 2004;43(4):607–16. 30. Watson EL, Greening NJ, Viana JL, Aulakh J, Bodicoat DH, Barratt J, et al. Progressive Resistance Exercise Training in CKD: A Feasibility Study. Am J Kidney Dis. 2015;66(2):249

2021 Renal Association

4. ffects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial Full Text available with Trip Pro

ffects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily (...) Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Eur Heart J Actions . 2021 Mar 31;42(13):1216-1227. doi: 10.1093/eurheartj/ehab094. Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial , , , , , , , , , , , , , , Collaborators, Affiliations Expand Collaborators DAPA-CKD Trial Committees

2021 EvidenceUpdates

5. Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study Full Text available with Trip Pro

the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Bisphosphonates increased bone mineral density for people with stage 3B+ chronic kidney disease but demonstrated renal toxicity, while failing to demonstrate antifracture effectiveness, and further research is needed. {{author}} {{($index , , , , , , , , , , , , & . Danielle E Robinson 1, † , M Sanni Ali 1, 2, † , Victoria Y Strauss 1, * , Leena Elhussein 1 , Bo Abrahamsen 3, 4 (...) Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find

2021 NIHR HTA programme

6. Anemia in Chronic Kidney Disease: An assessment of roxadustat

Anemia in Chronic Kidney Disease: An assessment of roxadustat Anemia in Chronic Kidney Disease - ICER Toggle Navigation Search: / / Anemia in Chronic Kidney Disease Anemia in Chronic Kidney Disease An assessment of roxadustat. Public Meeting February 2021 Assessment Status Closed Public Comments Closed stated: “Roxadustat represents an oral alternative for patients living with anemia from CKD, and as such, it may offer important advantages for those not receiving in-center hemodialysis. However (...) . This leaves large uncertainties about the balance of risks and benefits of roxadustat, and the votes of the CTAF panel confirmed these concerns.” For more information, please contact . View the Main Review February 11, 2021 9-2 PM PT Virtual A public meeting of the CTAF to deliberate and vote on evidence presented in ICER’s report on therapies for anemia in chronic kidney disease (CKD): Related Assessments & Policy Papers. Jul 2020 Mar 2018 Oct 2020 06/26/2020 - 07/15/2020 Open Input Period 07/20/2020

2021 California Technology Assessment Forum

7. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes Full Text available with Trip Pro

Consortium. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012;380:1662–1673. doi: 10.1016/S0140-6736(12)61350-6 - - van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey A, de Jong P, Gansevoort RT, van der Velde M, Matsushita K, et al. ; Chronic Kidney Disease Prognosis Consortium. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause (...) Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Show account info Close Account

2021 EvidenceUpdates

8. Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease

Department of Clinical Medicine, University of Copenhagen, Denmark (P.R.). 15 Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas (R.D.T.). PMID: 33186054 DOI: Item in Clipboard Full text links Cite Display options Display options Format Abstract Background: Dapagliflozin reduces the risk of end-stage renal disease in patients with chronic kidney disease. We examined the relative risk of cardiovascular and renal events in these patients and the effect of dapagliflozin (...) cardiovascular causes or hospitalization for heart failure, and prolonged survival in people with chronic kidney disease, with or without type 2 diabetes, independently of the presence of concomitant cardiovascular disease. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: . Keywords: cardiovascular diseases; heart failure; renal insufficiency, chronic; sodium-glucose transporter 2 inhibitors. Similar articles Jhund PS, Solomon SD, Docherty KF, Heerspink HJL, Anand IS, Böhm M, Chopra V

2021 EvidenceUpdates

9. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial

options Format Share Permalink Copy Page navigation Lancet Diabetes Endocrinol Actions . 2021 Jan;9(1):22-31. doi: 10.1016/S2213-8587(20)30369-7. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Renal Medicine, University College London, London, UK; The George Institute for Global Health (...) Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set

2021 EvidenceUpdates

10. Systematic review and meta-analysis of outcomes of lower extremity peripheral arterial interventions in patients with and without chronic kidney disease or end-stage renal disease

Systematic review and meta-analysis of outcomes of lower extremity peripheral arterial interventions in patients with and without chronic kidney disease or end-stage renal disease Systematic review and meta-analysis of outcomes of lower extremity peripheral arterial interventions in patients with and without chronic kidney disease or end-stage renal disease - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search (...) Permalink Copy Page navigation Review J Vasc Surg Actions . 2021 Jan;73(1):331-340.e4. doi: 10.1016/j.jvs.2020.08.032. Epub 2020 Sep 1. Systematic review and meta-analysis of outcomes of lower extremity peripheral arterial interventions in patients with and without chronic kidney disease or end-stage renal disease , , , , , , , , , , Affiliations Expand Affiliations 1 Section of Cardiovascular Medicine, Yale New Haven Hospital, New Haven, Conn. Electronic address: manantha@umn.edu. 2 Section

2021 EvidenceUpdates

11. Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease - Japanese Guideline on the Management of Asymptomatic Hyperuricemia Full Text available with Trip Pro

Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease - Japanese Guideline on the Management of Asymptomatic Hyperuricemia Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease - Japanese Guideline on the Management of Asymptomatic Hyperuricemia - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features (...) Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Circ J Actions . 2021 Jan 25;85(2):130-138. doi: 10.1253/circj.CJ-20-0406. Epub 2020 Dec 18. Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease - Japanese Guideline on the Management of Asymptomatic Hyperuricemia , , , , , , , , , Affiliations Expand Affiliations 1 Division of Regenerative

2021 Japanese Clinical Guidelines

12. Anaemia of Chronic Kidney Disease

synthesis is dropping: further iron therapy may be postponed. ? A rising ferritin level and a drop in TSAT suggest an inflammatory condition: a source of inflammation may be sought: sepsis, vascular access, surgery, recent hospitalisation: further iron therapy depends on target ferritin level and clinical scenario. Renal Association Clinical Practice Guideline – Anaemia of Chronic Kidney Disease – June 2017 26 ? Ongoing high requirements for IV iron to maintain a given ferritin level also point (...) Anaemia of Chronic Kidney Disease Clinical Practice Guideline Anaemia of Chronic Kidney Disease Final Version: June 2017 Updated: February 2020 Review Date: June 2022 Authors: Dr Ashraf Mikhail Consultant Nephrologist, Abertawe Bro Morgannwg University Health Board Christopher Brown Consultant Renal Pharmacist, Abertawe Bro Morgannwg University Health Board Jennifer Ann Williams Renal Anaemia Nurse Specialist, Abertawe Bro Morgannwg University Health Board Vinod Mathrani Consultant Physician

2020 Renal Association

13. Dapagliflozin in Patients with Chronic Kidney Disease. (Abstract)

Dapagliflozin in Patients with Chronic Kidney Disease. Patients with chronic kidney disease have a high risk of adverse kidney and cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease, with or without type 2 diabetes, is not known.We randomly assigned 4304 participants with an estimated glomerular filtration rate (GFR) of 25 to 75 ml per minute per 1.73 m2 of body-surface area and a urinary albumin-to-creatinine ratio (with albumin measured in milligrams (...) and creatinine measured in grams) of 200 to 5000 to receive dapagliflozin (10 mg once daily) or placebo. The primary outcome was a composite of a sustained decline in the estimated GFR of at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes.The independent data monitoring committee recommended stopping the trial because of efficacy. Over a median of 2.4 years, a primary outcome event occurred in 197 of 2152 participants (9.2%) in the dapagliflozin group and 312 of 2152

2020 NEJM

14. Effects of exercise on inflammation and nutrition outcomes in patients with chronic kidney disease: a protocol for systematic review and meta-analysis Full Text available with Trip Pro

Effects of exercise on inflammation and nutrition outcomes in patients with chronic kidney disease: a protocol for systematic review and meta-analysis Inplasy Protocol 859 - INPLASY.COM International Platform of Registered Systematic Review and Meta-analysis Protocols Main Menu Share this: Copyright © 2021 INPLASY.COM Powered by INPLASY.COM

2020 INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols

15. Thyroid Dysfunction and cardiovascular events in patients with chronic kidney disease: A protocol of systematic review and meta-analysis Full Text available with Trip Pro

Thyroid Dysfunction and cardiovascular events in patients with chronic kidney disease: A protocol of systematic review and meta-analysis Inplasy Protocol 856 - INPLASY.COM International Platform of Registered Systematic Review and Meta-analysis Protocols Main Menu Share this: Copyright © 2021 INPLASY.COM Powered by INPLASY.COM

2020 INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols

16. Traditional Chinese exercises in adults with chronic kidney disease: A protocol for systematic review and meta-analysis Full Text available with Trip Pro

Traditional Chinese exercises in adults with chronic kidney disease: A protocol for systematic review and meta-analysis Inplasy Protocol 850 - INPLASY.COM International Platform of Registered Systematic Review and Meta-analysis Protocols Main Menu Share this: Copyright © 2021 INPLASY.COM Powered by INPLASY.COM

2020 INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols

17. Calcium channel blockers for people with chronic kidney disease requiring dialysis. Full Text available with Trip Pro

Calcium channel blockers for people with chronic kidney disease requiring dialysis. Calcium channel blockers (CCBs) are used to manage hypertension which is highly prevalent among people with chronic kidney disease (CKD). The treatment for hypertension is particularly challenging in people undergoing dialysis.To assess the benefits and harms of calcium channel blockers in patients with chronic kidney disease requiring dialysis.We searched the Cochrane Kidney and Transplant Register of Studies (...) across studies. Well-designed RCTs, conducted in both adults and children with CKD requiring both haemodialysis and peritoneal dialysis, evaluating both dihydropyridine and non-dihydropyridine CCBs against other antihypertensives are required. Future research should be focused on outcomes relevant to patients (including death and cardiovascular disease), blood pressure changes, risk of side effects and healthcare costs to assist decision-making in clinical practice.Copyright © 2020 The Cochrane

2020 Cochrane

18. Conversion of Urine Protein-Creatinine Ratio or Urine Dipstick Protein to Urine Albumin-Creatinine Ratio for Use in Chronic Kidney Disease Screening and Prognosis : An Individual Participant-Based Meta-analysis. Full Text available with Trip Pro

Conversion of Urine Protein-Creatinine Ratio or Urine Dipstick Protein to Urine Albumin-Creatinine Ratio for Use in Chronic Kidney Disease Screening and Prognosis : An Individual Participant-Based Meta-analysis. Although measuring albuminuria is the preferred method for defining and staging chronic kidney disease (CKD), total urine protein or dipstick protein is often measured instead.To develop equations for converting urine protein-creatinine ratio (PCR) and dipstick protein to urine albumin (...) dipstick protein may help in CKD screening, staging, and prognosis.National Institute of Diabetes and Digestive and Kidney Diseases and National Kidney Foundation.

2020 Annals of Internal Medicine

19. Cardiovascular and Renal Outcomes with SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis Full Text available with Trip Pro

Cardiovascular and Renal Outcomes with SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis Cardiovascular and Renal Outcomes with SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis | Research Square Browse Tools & Services Your Cart See the published version (...) the effect of SGLT-2 inhibitors with that of GLP-1 RAs in type 2 DM patients with chronic kidney disease (CKD). We herein investigated the benefits of SGLT-2 inhibitors and GLP-1 RAs in CKD patients. Methods We performed a systematic literature search through July 2020. We selected randomized control trials that compared the risk of major adverse cardiovascular events (MACE) and a composite of renal outcomes. We performed a network meta-analysis to compare SGLT-2 inhibitors with GLP-1 RA indirectly. Risk

2020 Research Square

20. Management Options for an Older Adult With Advanced Chronic Kidney Disease and Dementia: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. (Abstract)

Management Options for an Older Adult With Advanced Chronic Kidney Disease and Dementia: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. About 15% of adults in the United States-37 million persons-have chronic kidney disease (CKD). Chronic kidney disease is divided into 5 groups, ranging from stage 1 to stage 5 CKD, whereas end-stage kidney disease (ESKD) is defined as permanent kidney failure. The treatment options for ESKD are kidney replacement therapy (KRT (...) ) and conservative management. The options for KRT include hemodialysis (either in-center or at home), peritoneal dialysis, and kidney transplant. Conservative management, a multidisciplinary model of care for patients with stage 5 CKD who want to avoid dialysis, is guided by patient values, preferences, and goals, with a focus on quality of life and symptom management. In 2015, the Kidney Disease Outcomes Quality Initiative recommended that patients with an estimated glomerular filtration rate below 30 mL/min

2020 Annals of Internal Medicine